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Malignant mesothelioma, a tumour frequently linked to past
occupational exposure to asbestos, arises from mesothelial cells of
the pleura, peritoneum or pericardium (Wagner et al, 1960).
Mesothelioma is characterized by a long latent period (35–40
years) (Browne, 1986; Yates et al, 1997) and due to the lack of
efficient treatment, its prognosis is very poor. From 1975 to 1990
there was an increasing trend in the incidence of mesotheliomas in
Finland, but since 1990 it has slowed down. Based on observations
from 1985 to 1995, by 2010 the annual incidence of mesothe-
liomas among men and women is expected to be around 40–50
and 10–20 cases respectively (Karjalainen et al, 1997).
Previous cytogenetic and molecular genetic studies have indi-
cated several chromosomal locations with frequent alterations in
mesothelioma (Tiainen et al, 1989; Hagemeijer et al, 1990;
Taguchi et al, 1993; Cheng et al, 1994; Lu et al, 1994; Zeiger et al,
1994; Bianchi et al, 1995; Sekido et al, 1995). However, no aber-
ration specific to mesothelioma has been detected. Comparative
genomic hybridization (CGH) analyses on primary mesothelioma
tumours and cell lines have revealed that loss of genetic material at
chromosome 14q is one of the most frequently occurring aberra-
tions (Kivipensas et al, 1996; Björkqvist et al, 1997, 1998; Balsara
et al, 1999). In this study we further verify the frequency and
pattern of deletions at 14q in primary mesothelioma tumours using
polymerase chain reaction (PCR) and 23 microsatellite markers
spanning the whole of the long arm of chromosome 14.
MATERIALS AND METHODS
Tumours and clinical characteristics of patients
Eighteen primary tumours of patients with malignant mesothe-
lioma were included in the microsatellite marker analysis. All of
the patients had undergone surgery at the Helsinki University
Central Hospital during years 1995–1997. Three of the patients
were females and 15 males. The mean age at diagnosis was 57
years (range 44–72 years). Thirteen patients had a clear history of
asbestos exposure. Three tumour samples were from patients with
stage 2 disease, whereas eight and seven samples were from
patients with stage 3 and 4 disease respectively. The median
survival of the patients was 16 months. The histological classifica-
tion of the tumours was performed by the Finnish Mesothelioma
Panel. Fourteen tumours were epithelial (nos 1–14), two mixed
(nos 15 and 16), one fibromatous (no. 17) and in one case the
histological subtype could not be determined (no. 18). CGH
analyses had previously been performed on eight of the tumours
(Table 1).
Tumour DNA was extracted from paraffin-embedded tissues
(nos 1–13 and 15–18) by a salting out procedure (Miller et al,
1988) or from fresh-frozen material (no. 14) according to standard
protocols. The proportion of malignant cells in the tumour samples
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00029 HUCH, Helsinki, Finlandwas at least 60%. Normal DNA from each patient was isolated
from peripheral blood samples according to standard methods.
Microsatellite marker analysis
A total of 23 dinucleotide microsatellite markers were used in the
analysis. The samples were first screened using 15 microsatellite
markers: D14S72, D14S283, D14S80, D14S1060, D14S75,
D14S269, D14S66, D14S63, D14S77, D14S74, D14S68, D14S81,
D14S65, D14S78 and D14S1007. These spanned the whole q-arm
with an average genetic distance of 9 cM (range 5.4–13.1 cM)
between the markers. To further refine the locations with the
highest number of tumours with loss of heterozygosity (LOH) or
allelic imbalance (AI), eight additional microsatellite markers
(D14S1003, D14S972, D14S64, D14S258, D14S277, D14S71,
D14S284 and D14S76) were analysed. The relative order of
markers and genetic distances between them were obtained from
the Généthon genetic linkage map (http: //www.genethon.fr) (Dib
et al, 1996). Cytogenetic locations of the markers were based
on the Genome Database (The Johns Hopkins University
BioInformatics Web Server) at http: //www.bis.med.jhmi.edu/.
The PCR reactions were carried out in an MJ Research PTC-
200 Peltier Thermal Cycler. The reaction was done in a 20 ml
volume containing 50 ng DNA, 10 mM Tris–HCl (pH 8.3), 50 mM
potassium chloride, 1.5 mM magnesium chloride, 0.001% gelatin
(w/v), 1% dimethyl sulphoxide (w/v), 0.5 mM of each primer,
200 mM each of dATP, dCTP, dGTP and dTTP, and 0.6 unit of
AmpliTaq DNA Polymerase (Perkin-Elmer, Branchburg, NJ,
USA). The following amplification programme was used: an
initial denaturation at 94°C for 4 min followed by 28 cycles of
30 s at 94°C, 1 min 15 s at 55°C, and 15 s at 72°C and then by a
6-min extension at 72°C. The annealing temperature for different
microsatellite markers varied between 55°C and 65°C. For some
of the samples the extension time was increased from 15 to 45 s.
The amplification product was diluted 1:1 in a 95% formamide
gel-loading buffer, denatured at 93°C for 3 min, after which 5 ml
was loaded on a 6% denaturing polyacrylamide sequencing gel
(National Diagnostics Inc., Atlanta, GA, USA). After the gel was
fixed in 10% citric acid, the PCR products were visualized by
silver staining. The gels were scanned using a UMAX Power Look
2000 (UMAX Data Systems Inc., Hsinchu, Taiwan).
The analysis was done visually and independently by two
observers by comparing the intensities between the alleles in
tumour DNA to those in normal DNA. Tumours homozygous for a
specific locus were defined as uninformative. LOH was observed
in heterozygous samples when one of the alleles in the tumour
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Table 1 Pattern and frequency of loss of heterozygosity (LOH) and allelic imbalance (AI) detected with 23 microsatellite markers at 14q in 18 primary
mesothelioma tumours
TumouraDNA was reduced in intensity relative to the remaining allele and
the alleles in the normal DNA. Other intensity differences were
interpreted merely as AIs. All reactions displaying LOH or AI
were repeated. If the allele pattern was interpreted as LOH in one
experiment and as AI in the other, it was considered to be an AI.
However, the reason some of the observed AIs were not deter-
mined as LOHs could be that tumour DNA was amplified more
efficiently than normal DNA. Moreover, previous CGH data of,
for instance, tumour no. 4 confirm the presence of loss of DNA
sequences at 14q, although allelotyping was interpreted as AI.
Therefore we refer to deletion for both LOH and AI.
RESULTS
Ten of 18 (56%) mesothelioma tumours displayed LOH or allelic
imbalance with at least one microsatellite marker at 14q (Table 1).
Eight of these were epithelial tumours, one a mixed tumour and
one a tumour with undetermined histology. Partial deletions of
varying lengths, detected as LOH or AI of some loci and as reten-
tion of heterozygosity of others, were more common than loss of
the entire q-arm. Deletions of all informative markers, revealing
deletion of the whole long arm which indicates monosomy 14,
were found in only one tumour (no. 18). In four tumours deletions
of several adjacent markers were observed, whereas the remaining
five tumours displayed deletions of two adjacent markers or only
at one marker. In some of these the marker that showed deletion
was, however, flanked by an uninformative marker or a marker,
whose status could not be determined.
Based on the results of the first 15 microsatellite markers
analysed, the highest number of tumours carrying a deletion was
found for markers D14S283 (five tumours) and D14S77 (five
tumours) (Table 1). The density of mapping was increased around
these markers by analysing additional eight markers. Based on the
results from all 23 markers, 14q11.1–q12 and 14q23–q24 were
found to be the most involved regions in deletions. Representative
results of some markers are presented in Figure 1. The highest
number of tumours displaying deletions at 14q11.1–q12 was
detected with markers D14S283 (five tumours; frequency: 31%),
D14S972 (seven tumours; frequency: 50%) and D14S64 (five
tumours; frequency: 45%). Four tumours had deletions with all
three markers. The highest number of tumours displaying dele-
tions at 14q23–q24 was observed with markers D14S258 (five
tumours; frequency: 45%), D14S77 (five tumours; frequency:
31%) and D14S284 (six tumours; frequency: 60%). Only one
tumour (frequency: 13%) displayed a deletion with marker
D14S277 (between D14S258 and D14S77) and no deletions were
detected with marker D14S71 (between D14S77 and D14S284;
Table 1).
Eight tumours displayed deletions at both 14q11.1–q12 and
14q23–q24 with at least one marker. Tumour no. 2, which
displayed deletions only in the proximal part of 14q, was uninfor-
mative at D14S258 but contained both alleles at loci detected with
markers D14S77 and D14S284. Tumour no. 7, which displayed
deletion at 14q23–q24 but not at 14q11.1–q12, was uninformative
at D14S64 but displayed retention of heterozygosity at both
D14S283 and D14S972 (Table 1).
Patients, in whose tumour DNA we detected deletions at 14q,
had a shorter median survival (12 months) than those without dele-
tions at 14q in their tumours (20 months). Five of the eight patients
with no detectable deletion at 14q in their tumours survived more
than 1.5 years compared to only two of the ten with a deletion at
14q in their tumours. However, the difference in survival between
these two groups, analysed using log-rank and Wilcoxon tests, was
not statistically significant. Nine out of 11 patients with stage 2 or
3 disease had deletions at 14q in their tumours, as compared to
only one of the seven patients with stage 4 disease (P = 0.013,
Fisher’s exact test, two-tailed). In nine of the 13 tumours from
patientswith a clear history of asbestos exposure, deletions at 14q
were detected, as compared to only one of the five patients with no
known exposure to asbestos (not statistically significant). The
small number of samples analysed does not allow decisive conclu-
sions to be drawn from the statistical analyses.
DISCUSSION
Eighteen primary malignant mesothelioma tumours were analysed
using 23 microsatellite markers spanning the whole long arm of
chromosome 14 in order to characterize the frequency and pattern
of deletions at 14q. Fifty-six per cent of the tumours displayed a
deletion. The percentage is much higher than that (24%) observed
in primary tumours by CGH (Kivipensas et al, 1996; Björkqvist et
al, 1997, 1998). However, this is not unexpected due to the small
partial deletions observed by allelotyping in some of the tumours
and because of the resolution limitation of the CGH method
(Kallioniemi et al, 1994). Recent allelotyping analyses at 1p and
6q on primary mesothelioma tumours have revealed frequencies of
61% (11/18) and 38% (6/16) for allelic loss respectively (Lee et al,
1996; Bell et al, 1997).
In eight of the tumours (nos 1, 2, 3, 4, 10, 13, 14 and 15) we
were able to compare the allelotyping results with previous CGH
data of 14q (Björkqvist et al, 1997, 1998). Loss of genetic material
at 14q was found by CGH in tumour nos 1, 3, 4 and 15. In all of
these we found deletions for several markers. Tumour nos 10, 13
and 14, which did not show any loss of DNA sequences at 14q by
CGH, did not display any deletion by allelotyping either. However,
tumour no. 2, whose CGH profile of 14q did not exceed the
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Figure 1 Representative results of microsatellite markers D14S283, D14S972, D14S258, D14S77, and D14S284. Tumour numbers are shown at top.
Locations of alleles are indicated with a dot. Arrowheads, LOH. Faint signals in the tumour lanes may result from normal cell contamination or intratumour
heterogeneity. T, primary tumour DNA; N, normal DNA from peripheral bloodthreshold for loss of genetic material, displayed deletions at the
proximal part of 14q by allelotyping.
In earlier cytogenetic analyses deletions at chromosome 14 have
not been among the most frequently observed chromosomal aber-
rations in mesothelioma. However, monosomy 14 has been
detected (Tiainen et al, 1989; Taguchi et al, 1993). The deletion
pattern that we observed in the present allelotyping analysis was
very complex. Only one of the tumours displayed deletion of all
informative markers revealing a loss of the whole chromosome.
Partial deletions of varying lengths were more common,
suggesting a complex mechanism, which perhaps involves both
chromosomal deletions and rearrangements, for inactivation of
tumour suppressor genes. Such complexity at the chromosomal
level was evident in a recent mesothelioma tumour analysed in our
diagnostic laboratory (data not shown). By G-banding a chaotic
karyotype was observed with a hypodiploid modal chromosome
number and seven unidentified marker chromosomes. Both copies
of chromosome 14 were missing. Chromosome painting analysis
using a chromosome 14-specific library probe revealed one of the
smaller markers to be composed of material from chromosome 14
[del(14q)] and part of chromosome 14 to be translocated to two
unidentified marker chromosomes. As a result there was a net loss
of genetic material from chromosome 14. This loss was further
mapped by CGH to 14qcen–q21. Taken together these results
manifest the complexity and suggest possible impact of deletions
at 14q in mesothelioma. Thus, it would appear that profound
chromosomal instability accumulates aberrant cells, of which
some exhibit genetic changes advantageous in tumorigenesis.
Although the deletion pattern in the present study was complex,
and most probably induced by chromosomal aberrations,
14q11.1–q12 and 14q23–q24 were found to be the most involved
regions in deletions. 14q11.1–q12 overlaps those regions that have
been found deleted in ovarian carcinoma and bladder cancer
(14q12–q13 and 14q12 respectively). However, the critical
markers in these studies, in contrast to ours, were all located distal
to D14S64 (Chang et al, 1995; Bandera et al, 1997). In lung carci-
noma the highest frequency of LOH was found with marker
D14S261 at 14q11.1–q11.2 (centromeric to D14S72) (Abujiang et
al, 1998). We observed deletions at 14q23–q24 by microsatellite
markers D14S258, D14S77 and D14S284 in five, five and six
tumours respectively. Interestingly, Schwerdtle et al have found
that marker D14S258 also exhibits frequent allelic loss in renal
oncocytomas, implicating a locus for a tumour suppressor gene
possibly involved in different tumours (Schwerdtle et al, 1997).
Furthermore, 14q24–q32 has been found to be the smallest over-
lapping segment of deletions in both nonpapillary renal cell carci-
noma and meningiomas (Simon et al, 1995; Herbers et al, 1997).
No tumour suppressor genes have so far been assigned to 14q.
However, the APEX gene located at 14q11.2–q12 falls into one of
the regions that we found to be most involved in deletions. This
gene encodes a DNA repair enzyme called APEX nuclease or
apurinic endonuclease (APE), which initiates the repair of abasic
sites caused by mutagens such as free oxygen radicals (Demple et
al, 1991; Harrison et al, 1992). Such oxygen radicals, with DNA-
damaging properties, are known to be released by macrophages
exposed to asbestos (Hansen and Mossman, 1987; Goodglick and
Kane, 1990). Inactivation of enzymes involved in DNA repair,
including APEX, would prevent their functions and leave the
damaged DNA uncorrected, thereby causing mutations. The
expression level of APEX in mesothelioma has, as far as we know,
not been studied. However, increased production of APEX has
been detected in rat pleural mesothelial cells, but not in Met5A
cells (an immortalized human mesothelial cell line), as a response
to asbestos exposure (Fung et al, 1998).
In conclusion, the present microsatellite marker analysis
suggests that genomic losses at 14q are more frequent in meso-
thelioma than previously recognized by other methods. Partial
deletions were more common than loss of the whole arm and
sometimes included only a small chromosomal segment. Although
the deletion pattern seems to be complex, deletion at both
14q11.1–q12 and 14q23–q24 was observed in eight of the ten
tumours exhibiting losses. The two remaining tumours had dele-
tion either at 14q11.1–q12 or 14q23–q24.
These chromosomal regions provide a good basis for further
fine-mapping and can help in pinpointing the locations of genes,
which may be important in the tumorigenesis of malignant
mesothelioma.
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